For the quarter ended March 2024, Henry Schein (HSIC) reported revenue of $3.17 billion, up 3.7% over the same period last year. EPS came in at $1.10, compared to $1.21 in the year-ago quarter.The reported revenue represents a surprise of -1.76% over the Zacks Consensus Estimate of $3.23 billion. With the consensus EPS estimate being $0.99, the EPS surprise was +11.11%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Henry Schein, Inc. (HSIC) registered adjusted earnings per share (EPS) of $1.10 in the first quarter of 2024, down 9.1% from the year-ago period’s adjusted EPS. However, the metric exceeded the Zacks Consensus Estimate by 11.1%.Revenues in DetailHenry Schein reported net sales of $3.17 billion in the first quarter, up 3.7% year over year. The metric lagged the Zacks Consensus Estimate by 1.8%. The year-over-year upside reflects an internal sales decline of 1.8%.On a geographic basis, the company recorded sa ...

Henry Schein (HSIC) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $1.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this health care products maker would post earnings of $0.70 per share when it actually produced earnings of $0.66, delivering a surprise of -5.71%.Over the last four quarte ...

FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS SOLID FIRST-QUARTER 2024 FINANCIAL RESULTS AND UPDATES 2024 FINANCIAL GUIDANCE ● First-quarter 2024 sales growth of 3.7%, GAAP diluted EPS of $0.72 and non-GAAP diluted EPS of $1.10 ● Tightens total sales growth guidance range to 8% to 10%, reflecting continued recovery from last year’s cyber incident and a strong pipeline of new specialty products and software innovation ● Affirms 2024 non-GAAP diluted EPS guidance of $5.00 to $5.16 and 2024 Adjusted EBITDA growth ...

Wall Street analysts forecast that Henry Schein (HSIC) will report quarterly earnings of $0.99 per share in its upcoming release, pointing to a year-over-year decline of 18.2%. It is anticipated that revenues will amount to $3.23 billion, exhibiting an increase of 5.5% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior ...

公司业绩展望 - 公司预计2024年第一季度的运营结果可能反映出网络安全事件的持续影响[2] - 预计对口内扫描仪的强劲需求将在报告季度持续[7] - Zacks Consensus Estimate预计HSIC的2024年第一季度营收为32.3亿美元[15] 业务表现 - 公司的直接营销和客户服务能力可能有助于减轻网络安全事件的残留影响[4] - 公司在技术和增值服务方面取得了显著的销售增长[11] - Henry Schein的全球牙科专业产品有望继续在全球市场中占据市场份额[8] 市场趋势 - 在2024年第一季度，医疗业务可能会看到强劲的点对点诊断销售[5] - 由于网络安全事件，传统和数字牙科设备的销售下降，但在2024年第一季度可能会有所好转[6] - Henry Schein可能在2022-2024年的战略计划中取得了显著进展[14] 财务预期 - Zacks Consensus Estimate预计其2024年第一季度每股收益为99美分[16]

Henry Schein (HSIC) is well-positioned to gain from its extensive global foothold and diverse channel mix. However, unfavorable currency movement and global economic uncertainties continue to affect the business. The stock carries a Zacks Rank #3 (Hold) currently.Henry Schein’s business boasts a broad global footprint with 61 distribution centers. Apart from North America, the company has a presence in Australia and New Zealand as well as in emerging nations like China, Brazil, Israel, the Czech Republic an ...

公司业务发展 - Henry Schein, Inc.通过扩大全球数字牙科业务的战略，预计未来几个季度将会实现增长[1] - 公司通过收购和合作不断推动营收增长[1] - 公司市值为90.9亿美元，预计2024年盈利将增长12.7%[4] - 公司积极推广数字工作流程，为牙科业务提供多样化产品组合和增值服务[5] - 公司通过收购和合作扩大业务范围，加速实施战略计划[7] - 公司进入骨科市场极端领域，增加家庭医疗产品平台的收入基础[8] - 公司通过收购Biotech Dental和S.I.N. Implant System扩大数字工作流程解决方案[9] - 公司在数字临床工作流程解决方案方面取得进展，包括AI技术的推广[11] 公司业绩展望 - 公司在2023年第四季度，牙科专业产品销售受到收购和植入物等领域的有机增长推动[6] - 公司在数字临床工作流程解决方案方面取得进展，包括AI技术的推广[11] - Zacks对公司2024年的盈利预期为每股5.07美元，营收预期为134.1亿美元[16][17] 公司风险因素 - 公司在2023年10月经历了一次网络安全事件，对业务产生了负面影响[12] - 公司估计网络安全事件导致2023年第四季度销售额减少3.5亿至4亿美元，对运营利润产生负面影响[13] - 全球宏观经济环境的问题可能影响Henry Schein的财务运营[15]

Henry Schein, Inc. (HSIC) has recently completed the acquisition of orthopedic player TriMed for an undisclosed financial term. Integration of TriMed’s business will help the company to provide a wider range of surgical solutions to the existing Integrated Delivery Networks and Ambulatory Surgery Center customers. This will strengthen HSIC’s long-standing relationship with them.Headquartered in Santa Clarita, CA, TriMed is a global developer of solutions for the orthopedic treatment of lower extremities (fo ...

Henry Schein to Maximize Viome's Reach Among Dental and Medical Practices With Patient-Centric and Preventive Models of Care BELLEVUE, Wash., April 2, 2024 /PRNewswire/ -- Viome, a leading innovator of health technology and personalized health solutions, is partnering with Henry Schein to provide better access to Viome's Oral Health Pro™ With CancerDetect™.* Viome's laboratory-developed test* helps detect early biomarkers of oral and throat cancers, enhancing practitioners' ability to effectively harness th ...